Micromet to Report Blinatumomab Data at June Medical Conferences

First presentation of data from Phase 2 trial of blinatumomab in patients with relapsed/refractory ALL

BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at two upcoming medical meetings:

European Hematology Association Annual Congress
June 9 - 12, 2011, London, UK
Abstract title: Clinical activity of the anti-CD19 BiTE blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL): Interim results of a phase 2 study
Abstract number: 844
Presentation date and time: Saturday, June 11, 5:30 – 6:45 PM GMT
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany

A copy of the abstract can be found at: www.ehaweb.org/

11th International Congress on Malignant Lymphoma
June 15 – 18, 2011, Lugano, Switzerland
Abstract title: Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin’s lymphoma (NHL) including MCL and DLBCL
Abstract number: 068
Presentation date and time: Thursday, June 16, 2:45 – 3 PM CET
First author: Marie Elisabeth Goebeler, MD, University of Wuerzburg, Wuerzburg, Germany

A copy of the abstract will be posted to: www.lymphcon.ch/

About Blinatumomab

Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non Hodgkin's lymphomas.

Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.


Micromet, Inc.
Director, Corporate Communications
Jennifer Neiman, 240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Research  Science